S. Constantine

672 total citations
27 papers, 477 citations indexed

About

S. Constantine is a scholar working on Pulmonary and Respiratory Medicine, Epidemiology and Pathology and Forensic Medicine. According to data from OpenAlex, S. Constantine has authored 27 papers receiving a total of 477 indexed citations (citations by other indexed papers that have themselves been cited), including 11 papers in Pulmonary and Respiratory Medicine, 10 papers in Epidemiology and 5 papers in Pathology and Forensic Medicine. Recurrent topics in S. Constantine's work include Cystic Fibrosis Research Advances (7 papers), Inflammatory Myopathies and Dermatomyositis (7 papers) and Systemic Sclerosis and Related Diseases (4 papers). S. Constantine is often cited by papers focused on Cystic Fibrosis Research Advances (7 papers), Inflammatory Myopathies and Dermatomyositis (7 papers) and Systemic Sclerosis and Related Diseases (4 papers). S. Constantine collaborates with scholars based in United States, United Kingdom and Sri Lanka. S. Constantine's co-authors include Barbara White, Nancy Dgetluck, Gary Elfring, K. De Boeck, Temitayo Ajayi, Samit Hirawat, Isabelle Sermet‐Gaudelus, A. Reha, F. Vermeulen and Janine Fritsch and has published in prestigious journals such as SHILAP Revista de lepidopterología, American Journal of Respiratory and Critical Care Medicine and Annals of the Rheumatic Diseases.

In The Last Decade

S. Constantine

24 papers receiving 467 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
S. Constantine United States 9 201 121 99 94 93 27 477
N. Just France 11 110 0.5× 118 1.0× 49 0.5× 36 0.4× 17 0.2× 29 517
Kathleen Kelley United States 7 85 0.4× 76 0.6× 23 0.2× 24 0.3× 94 1.0× 12 382
Juan Manuel Povedano Spain 7 183 0.9× 127 1.0× 26 0.3× 51 0.5× 17 0.2× 13 488
J.‐P. Rihoux Belgium 19 134 0.7× 106 0.9× 141 1.4× 13 0.1× 32 0.3× 41 995
Neil J. Korman United States 6 16 0.1× 36 0.3× 60 0.6× 86 0.9× 168 1.8× 8 459
Arianna Zanca Italy 11 18 0.1× 62 0.5× 16 0.2× 68 0.7× 55 0.6× 23 394
Konstantinos I. Papadopoulos Thailand 13 48 0.2× 73 0.6× 41 0.4× 48 0.5× 9 0.1× 31 415
Jay A. Nadel United States 9 129 0.6× 110 0.9× 18 0.2× 23 0.2× 9 0.1× 11 387
L Pickford United States 8 56 0.3× 77 0.6× 17 0.2× 29 0.3× 23 0.2× 9 424
Patricia Calleja Spain 10 46 0.2× 68 0.6× 6 0.1× 75 0.8× 95 1.0× 16 308

Countries citing papers authored by S. Constantine

Since Specialization
Citations

This map shows the geographic impact of S. Constantine's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by S. Constantine with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites S. Constantine more than expected).

Fields of papers citing papers by S. Constantine

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by S. Constantine. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by S. Constantine. The network helps show where S. Constantine may publish in the future.

Co-authorship network of co-authors of S. Constantine

This figure shows the co-authorship network connecting the top 25 collaborators of S. Constantine. A scholar is included among the top collaborators of S. Constantine based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with S. Constantine. S. Constantine is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Constantine, S., et al.. (2024). An unusual presentation of dermatomyositis: dermatomyositis sine dermatitis presenting with rapidly progressive myositis. SHILAP Revista de lepidopterología. 3(2). 108–112.
2.
Werth, Victoria P., S.M. Peña, Majid Zeidi, et al.. (2022). Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial. Journal of Investigative Dermatology. 142(10). 2651–2659.e1. 37 indexed citations
3.
Spiera, Robert, Masataka Kuwana, Dinesh Khanna, et al.. (2021). OP0171 PHASE 3 TRIAL OF LENABASUM, A CB2 AGONIST, FOR THE TREATMENT OF DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS (DCSSC). Annals of the Rheumatic Diseases. 80. 102–103. 8 indexed citations
4.
Werth, Victoria P., Josef Symon S. Concha, Joyce Okawa, et al.. (2021). POS0315 LONG-TERM SAFETY AND EFFICACY OF LENABASUM DURING 3 YEARS IN AN OPEN-LABEL EXTENSION (OLE) OF A PHASE 2 STUDY OF LENABASUM IN REFRACTORY SKIN DISEASE IN DERMATOMYOSITIS (DM). Annals of the Rheumatic Diseases. 80. 383–384. 2 indexed citations
5.
Spiera, Robert, Laura K. Hummers, Leland W.K. Chung, et al.. (2020). Safety and Efficacy of Lenabasum in a Phase II, Randomized, Placebo‐Controlled Trial in Adults With Systemic Sclerosis. Arthritis & Rheumatology. 72(8). 1350–1360. 72 indexed citations
6.
Chmiel, James F., Patrick A. Flume, D.G. Downey, et al.. (2020). Safety and efficacy of lenabasum in a phase 2 randomized, placebo-controlled trial in adults with cystic fibrosis. Journal of Cystic Fibrosis. 20(1). 78–85. 58 indexed citations
7.
Yesudian, Paul Devakar, et al.. (2020). Disseminated Mycobacterium simiae infection in a patient with adult-onset immunodeficiency due to anti-interferon-gamma antibodies – a case report. BMC Infectious Diseases. 20(1). 258–258. 7 indexed citations
8.
Werth, Victoria P., David R. Pearson, Joyce Okawa, et al.. (2019). 610 Safety and efficacy of lenabasum in refractory skin-predominant dermatomyositis subjects treated on an open-label extension of trial JBT101-DM-001. Journal of Investigative Dermatology. 139(5). S105–S105. 5 indexed citations
9.
Herath, H. M. M. T. B., et al.. (2019). Scleredema associated with immunoglobulin A-κ smoldering myeloma: a case report and review of the literature. SHILAP Revista de lepidopterología. 13(1). 145–145. 5 indexed citations
10.
Werth, Victoria P., Chester V. Oddis, Ingrid E. Lundberg, et al.. (2019). SAT0303 DESIGN OF PHASE 3 STUDY OF LENABASUM FOR THE TREATMENT OF DERMATOMYOSITIS. Annals of the Rheumatic Diseases. 78. 1228–1228. 7 indexed citations
11.
Spiera, Robert, Laura K. Hummers, Leland W.K. Chung, et al.. (2019). OP0325 SAFETY AND EFFICACY OF LENABASUM IN AN OPEN-LABEL EXTENSION OF A PHASE 2 STUDY IN DIFFUSE CUTANEOUS SYSTEMIC SCLEROSIS SUBJECTS (DCSSC). Annals of the Rheumatic Diseases. 78. 245–246. 3 indexed citations
12.
Werth, Victoria P., David R. Pearson, Rui Feng, et al.. (2019). OP0241 SAFETY AND EFFICACY OF LENABASUM IN AN OPEN-LABEL EXTENSION OF A PHASE 2 STUDY OF LENABASUM IN REFRACTORY SKIN-PREDOMINANT DERMATOMYOSITIS (DM) SUBJECTS. Annals of the Rheumatic Diseases. 78. 199–200. 3 indexed citations
13.
Werth, V., S.M. Peña, Ruofei Feng, et al.. (2018). 605 Study of safety and efficacy of lenabasum, a cannabinoid receptor type 2 agonist, in refractory skin-predominant dermatomyositis. Journal of Investigative Dermatology. 138(5). S103–S103. 5 indexed citations
14.
Werth, Victoria P., Joyce Okawa, David R. Pearson, et al.. (2018). SAT0512 Safety and efficacy of lenabasum in refractory skin-predominant dermatomyositis subjects treated in an open label extension of trial jbt101-dm-001. Annals of the Rheumatic Diseases. 77. 1111–1112. 8 indexed citations
15.
16.
Bilton, Diana, Tacjana Pressler, Isabelle Fajac, et al.. (2014). Interim data from a long-term safety, tolerability, and efficacy study of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonas aeruginosa infection. 44. 3445.
17.
Kerem, Eitan, Michael Wilschanski, Thea Pugatsch, et al.. (2011). Ambulatory quantitative waking and sleeping cough assessment in patients with cystic fibrosis. Journal of Cystic Fibrosis. 10(3). 193–200. 11 indexed citations
18.
Kerem, Eitan, M. Wilschanski, K. De Boeck, et al.. (2011). 65 Phase 3 study of ataluren (PTC124®) in nonsense mutation cystic fibrosis (nmCF): baseline data. Journal of Cystic Fibrosis. 10. S17–S17. 6 indexed citations
19.
Sermet‐Gaudelus, Isabelle, K. De Boeck, Georges Casimir, et al.. (2010). Ataluren (PTC124) Induces Cystic Fibrosis Transmembrane Conductance Regulator Protein Expression and Activity in Children with Nonsense Mutation Cystic Fibrosis. American Journal of Respiratory and Critical Care Medicine. 182(10). 1262–1272. 184 indexed citations
20.
Kumarasinghe, M. Priyanthi & S. Constantine. (1998). Non-diagnostic smears in aspiration cytology of palpable breast lumps.. PubMed. 27(2). 161–7. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by N. Just Breakdown of academic impact, for papers by Kathleen Kelley Breakdown of academic impact, for papers by Juan Manuel Povedano Breakdown of academic impact, for papers by J.‐P. Rihoux Breakdown of academic impact, for papers by Neil J. Korman Breakdown of academic impact, for papers by Arianna Zanca Breakdown of academic impact, for papers by Konstantinos I. Papadopoulos Breakdown of academic impact, for papers by Jay A. Nadel Breakdown of academic impact, for papers by L Pickford Breakdown of academic impact, for papers by Patricia Calleja
Rankless by CCL
2026